Sanara MedTech to Present at the Piper Sandler 36th Annual Healthcare Conference on December 4th
Sanara MedTech (Nasdaq: SMTI), a medical technology company specializing in surgical, chronic wound, and skincare markets, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The event will take place at The Lotte New York Palace from December 3-5, 2024. Ron Nixon, the Company's Chairman and CEO, will deliver a presentation to investors on December 4 at 11:50 a.m. Eastern Time. Presentation materials will be available on the company's investor relations website before the event, along with a live audio webcast and replay option.
Sanara MedTech (Nasdaq: SMTI), un'azienda di tecnologia medica che si specializza nei mercati chirurgico, delle ferite croniche e della cura della pelle, ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Salute di Piper Sandler. L'evento si svolgerà presso il Lotte New York Palace dal 3 al 5 dicembre 2024. Ron Nixon, Presidente e Amministratore Delegato dell'azienda, terrà una presentazione per gli investitori il 4 dicembre alle 11:50 ora orientale. I materiali della presentazione saranno disponibili sul sito web delle relazioni con gli investitori dell'azienda prima dell'evento, insieme a una trasmissione audio in diretta e un'opzione di replay.
Sanara MedTech (Nasdaq: SMTI), una empresa de tecnología médica que se especializa en los mercados de cirugía, heridas crónicas y cuidado de la piel, ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. El evento se llevará a cabo en el Lotte New York Palace del 3 al 5 de diciembre de 2024. Ron Nixon, el Presidente y CEO de la empresa, realizará una presentación a los inversores el 4 de diciembre a las 11:50 a.m. hora del este. Los materiales de la presentación estarán disponibles en el sitio web de relaciones con los inversores de la empresa antes del evento, junto con una transmisión de audio en vivo y una opción de repetición.
Sanara MedTech (Nasdaq: SMTI)는 수술, 만성 상처 및 피부 관리 시장을 전문으로 하는 의료 기술 회사로, Piper Sandler 제36회 연례 의료 회의에 참가할 것이라고 발표했습니다. 이 행사는 2024년 12월 3일부터 5일까지 롯데 뉴욕 팰리스에서 열릴 예정입니다. 론 닉슨 회사 회장이자 CEO가 12월 4일 동부 표준시 기준 오전 11시 50분에 투자자에게 발표를 할 것입니다. 발표 자료는 이벤트 전에 회사의 투자자 관계 웹사이트에서 제공될 예정이며, 라이브 오디오 웹캐스트와 반복 재생 옵션도 제공됩니다.
Sanara MedTech (Nasdaq: SMTI), une entreprise de technologie médicale spécialisée dans les secteurs de la chirurgie, des plaies chroniques et des soins de la peau, a annoncé sa participation à la 36ème Conférence Annuelle sur la Santé de Piper Sandler. L'événement se déroulera au Lotte New York Palace du 3 au 5 décembre 2024. Ron Nixon, Président et Directeur Général de l'entreprise, fera une présentation aux investisseurs le 4 décembre à 11h50, heure de l'Est. Les documents de présentation seront disponibles sur le site web des relations avec les investisseurs de l'entreprise avant l'événement, ainsi qu'une diffusion audio en direct et une option de rediffusion.
Sanara MedTech (Nasdaq: SMTI), ein Medizintechnikunternehmen, das sich auf die Bereiche Chirurgie, chronische Wunden und Hautpflege spezialisiert hat, hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler bekannt gegeben. Die Veranstaltung findet vom 3. bis 5. Dezember 2024 im Lotte New York Palace statt. Ron Nixon, der Vorsitzende und CEO des Unternehmens, wird am 4. Dezember um 11:50 Uhr Eastern Time eine Präsentation für Investoren halten. Die Präsentationsmaterialien werden vor der Veranstaltung auf der Website der Investor Relations des Unternehmens verfügbar sein, zusammen mit einem Live-Audio-Webcast und einer Replay-Option.
- None.
- None.
FORT WORTH, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that Ron Nixon, the Company’s Chairman and Chief Executive Officer, will present at the Piper Sandler 36th Annual Healthcare Conference, which is being held at The Lotte New York Palace in New York, NY from December 3 – 5, 2024. Mr. Nixon will deliver a presentation to investors on Wednesday, December 4 at approximately 11:50 a.m. Eastern Time.
The presentation materials for the conference will be posted to the Company’s investor relations website, https://sanaramedtech.com/investor-relations/, prior to the presentation. A live audio webcast of the presentation will also be accessible under the “Events” section of the Company’s investor relations website at https://sanaramedtech.com/investor-relations/. An archive of the webcast will be available for replay following the conference.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. The Company markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings and offers wound care and dermatology virtual consultation services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX® Surgical Activated Collagen, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN™ Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, TEXAGEN® Amniotic Membrane Allograft, and BIASURGE® Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS® Antimicrobial Wound Gel, and BIAKŌS® Antimicrobial Skin and Wound Irrigation Solution. Sanara’s pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding our business strategy and mission, the development of new products, the timing of commercialization of our products, the regulatory approval process and expansion of the Company’s business in telehealth and wound care. These items involve risks, contingencies and uncertainties such as uncertainties associated with the development and process for obtaining regulatory approval for new products, our ability to build out our executive team, our ability to identify and effectively utilize the net proceeds of the term loan to support the Company’s growth initiatives, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s Securities and Exchange Commission filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Relations Contact:
Jack Powell or Mike Piccinino, CFA
ICR Healthcare
IR@sanaramedtech.com
FAQ
When will Sanara MedTech (SMTI) present at the Piper Sandler Healthcare Conference 2024?
Where can I watch Sanara MedTech's (SMTI) Piper Sandler Conference presentation?
Where is the Piper Sandler Healthcare Conference 2024 being held?
What markets does Sanara MedTech (SMTI) operate in?
